Peroxisomal proliferators induce in rodents hepatic hyperplasia and hypertrophy; the significant increase in the peroxisomal population is accompanied by specific and reversible induction of some peroxisomal enzymes. In suckling rats born from clofibrate-treated mothers, a massive removal of proliferated organelles occurs within 3 days of recovery. In the present paper we examined the early stages of the recovery period in liver of male rats treated with clofibrate for 5 days. The lysosomal involvement in the removal of drug-induced peroxisomes was investigated under physiological conditions, ie in the absence of inhibitors of the autophagic process. Biochemical results indicate that peroxisomal beta-oxidation, but not catalase activity, re...
Certain lipid-regulating agents induce hepatomegaly, hepatic peroxisome proliferation and hepatocarc...
The effect of endotoxin on lysosomes, lysosomal acid phosphatase and β-glucuronidase was studied in ...
Introduction. Fenofibrate (FN) is a hypolipemic drug used for the treatment of mixed dyslipidemia. S...
Following short treatments with peroxisomal proliferators rodent liver undergoes a significant incre...
AbstractDegradation of the peroxisomal enzymes fatty acyl-CoA oxidase and catalase was studied in he...
Morphological and morphometric parameters (volume density (Vv), numerical density(NA) and mean diame...
Liver peroxisomes during prenatal development were studied by means of morphological and morphometri...
Changes in the activities of two peroxisomal enzymes (catalase and thiolase), some parameters relate...
The mechanism of induction of peroxisome proliferation by xenobiotics was investigated. Firstly, the...
AbstractRemoval of a peroxisome proliferator from the diet triggered the degradation of peroxisomes ...
The membrane fluidity of liver peroxisomes from normal and clofibrate-treated rats was investigated ...
Rat hepatocytes were cultured for 72 h with or without the addition of 0.5 rriM clofibric acid. The ...
An ultrastructural and biochemical study of the toxic and hypoglycaemic effects of hypoglycin and pe...
Like mitochondria, peroxisomes produce reactive oxygen species (ROS), compounds which have been impl...
AbstractDietary treatment of male C57B1/6 mice with clolibrate, nafenopin or WY-14.643 resulted in a...
Certain lipid-regulating agents induce hepatomegaly, hepatic peroxisome proliferation and hepatocarc...
The effect of endotoxin on lysosomes, lysosomal acid phosphatase and β-glucuronidase was studied in ...
Introduction. Fenofibrate (FN) is a hypolipemic drug used for the treatment of mixed dyslipidemia. S...
Following short treatments with peroxisomal proliferators rodent liver undergoes a significant incre...
AbstractDegradation of the peroxisomal enzymes fatty acyl-CoA oxidase and catalase was studied in he...
Morphological and morphometric parameters (volume density (Vv), numerical density(NA) and mean diame...
Liver peroxisomes during prenatal development were studied by means of morphological and morphometri...
Changes in the activities of two peroxisomal enzymes (catalase and thiolase), some parameters relate...
The mechanism of induction of peroxisome proliferation by xenobiotics was investigated. Firstly, the...
AbstractRemoval of a peroxisome proliferator from the diet triggered the degradation of peroxisomes ...
The membrane fluidity of liver peroxisomes from normal and clofibrate-treated rats was investigated ...
Rat hepatocytes were cultured for 72 h with or without the addition of 0.5 rriM clofibric acid. The ...
An ultrastructural and biochemical study of the toxic and hypoglycaemic effects of hypoglycin and pe...
Like mitochondria, peroxisomes produce reactive oxygen species (ROS), compounds which have been impl...
AbstractDietary treatment of male C57B1/6 mice with clolibrate, nafenopin or WY-14.643 resulted in a...
Certain lipid-regulating agents induce hepatomegaly, hepatic peroxisome proliferation and hepatocarc...
The effect of endotoxin on lysosomes, lysosomal acid phosphatase and β-glucuronidase was studied in ...
Introduction. Fenofibrate (FN) is a hypolipemic drug used for the treatment of mixed dyslipidemia. S...